Evidence map›Paper›PMID 37961452›Full record

ArticlebioRxiv : the preprint server for biology2023

The mycobacterial glycoside hydrolase LamH enables capsular arabinomannan release and stimulates growth.

Aaron Franklin, Abigail J Layton, Todd Mize, Vivian C Salgueiro, Rudi Sullivan, Samuel T Benedict, Sudagar S Gurcha, Itxaso Anso, Gurdyal S Besra, Manuel Banzhaf and 7 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 4 countries.

Aaron FranklinSchool of Biosciences, University of Birmingham, Birmingham, U.K., B15 2TT.ORCID 0009-0006-0472-5895
Abigail J LaytonSchool of Biosciences, University of Birmingham, Birmingham, U.K., B15 2TT.
Todd MizeSchool of Biosciences, University of Birmingham, Birmingham, U.K., B15 2TT.ORCID 0000-0002-0261-1580
Vivian C SalgueiroDepartment of Preventive Medicine, Public Health and Microbiology. School of Medicine. Universidad Autonoma de Madrid, 28029 Madrid, Spain.
Rudi SullivanSchool of Biosciences, University of Birmingham, Birmingham, U.K., B15 2TT.
Samuel T BenedictSchool of Biosciences, University of Birmingham, Birmingham, U.K., B15 2TT.ORCID 0000-0002-8941-3703
Sudagar S GurchaSchool of Biosciences, University of Birmingham, Birmingham, U.K., B15 2TT.
Itxaso AnsoStructural Glycobiology Laboratory, Biocruces Health Research Institute, Barakaldo, Bizkaia, 48903, Spain.ORCID 0000-0002-4106-8031
Gurdyal S BesraSchool of Biosciences, University of Birmingham, Birmingham, U.K., B15 2TT.ORCID 0000-0002-5605-0395
Manuel BanzhafSchool of Biosciences, University of Birmingham, Birmingham, U.K., B15 2TT.ORCID 0000-0002-4682-1037
Andrew L LoveringSchool of Biosciences, University of Birmingham, Birmingham, U.K., B15 2TT.ORCID 0000-0002-1856-7975
Spencer J WilliamsSchool of Chemistry and Bio21 Molecular Science and Biotechnology Institute, University of Melbourne, Parkville, Victoria 3010, Australia.ORCID 0000-0001-6341-4364
Marcelo E GuerinStructural Glycobiology Laboratory, Department of Structural and Molecular Biology; Molecular Biology Institute of Barcelona (IBMB), Spanish National Research Council (CSIC), Barcelona Science Park, c/Baldiri Reixac 4-8, Tower R, 08028 Barcelona, Catalonia, Spain.ORCID 0000-0001-9524-3184
Nichollas E ScottDepartment of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne 3000, Australia.ORCID 0000-0003-2556-8316
Rafael Prados-RosalesDepartment of Preventive Medicine, Public Health and Microbiology. School of Medicine. Universidad Autonoma de Madrid, 28029 Madrid, Spain.ORCID 0000-0001-5964-0166
Elisabeth C LoweNewcastle University Biosciences Institute, Medical School, Newcastle University, Newcastle upon Tyne, U.K., NE2 4HH.ORCID 0000-0001-9812-0614
Patrick J MoynihanSchool of Biosciences, University of Birmingham, Birmingham, U.K., B15 2TT.ORCID 0000-0003-4182-6223
University of Birmingham · GBUniversidad Autónoma de Madrid · ESBioCruces Health research Institute · ESBiotechnology Institute · USConsejo Superior de Investigaciones Científicas · ESNewcastle University · GBThe University of Melbourne · AU

Funding

Gatekeeping glycan metabolism in the human gut microbiomeR01GM148075 · NIGMS · EMORY UNIVERSITY · PI ERIC JOHN SUNDBERG · 2023 to 2026
$1.7M
NIGMS NIH HHS R01 GM148075Wellcome Trust
6 · The paper itself

Abstract

Mycobacterial glycolipids are important cell envelope structures that drive host-pathogen interactions. Arguably, the most important amongst these are lipoarabinomannan (LAM) and its precursor, lipomannan (LM), which are both trafficked out of the bacterium to the host via unknown mechanisms. An important class of exported LM/LAM is the capsular derivative of these molecules which is devoid of its lipid anchor. Here, we describe the identification of a glycoside hydrolase family 76 enzyme that we term LamH which specifically cleaves α-1,6-mannoside linkages within LM and LAM, driving its export to the capsule releasing its phosphatidyl-

Identifiers

PMID37961452
PMCPMC10634837
OpenAlexW4388189850

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.